SCHEDULE 13G/A 0001104659-25-112051 0001952142 XXXXXXXX LIVE 1 Common stock, par value $0.0001 per share 12/31/2025 0001840233 Xilio Therapeutics, Inc. 98422T100 828 Winter Street, Suite 300 Waltham MA 02451 Rule 13d-1(b) StemPoint Capital LP DE 0.00 6030028.00 0.00 6030028.00 6030028.00 N 8.4 IA StemPoint Capital Management GP LLC DE 0.00 6030028.00 0.00 6030028.00 6030028.00 N 8.4 OO StemPoint Capital Management GP LLC is a limited liability company. Michelle Ross X1 0.00 6030028.00 0.00 6030028.00 6030028.00 N 8.4 HC IN Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, MA, 02451 This filing is being jointly filed by StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons" and each a "Reporting Person"). The business addresses of each Reporting Person is: 520 Madison Avenue, 19th Floor New York, NY 10022 StemPoint Capital LP is a limited partnership organized under the laws of the State of Delaware. StemPoint Capital Management GP LLC is a limited liability company organized under the laws of the State of Delaware. Michelle Ross is a citizen of the United States of America. N IA HC Items 5-9 of each cover page are incorporated by reference. Each Reporting Person may be deemed to be the beneficial owner of 6,030,028 Shares of the issuer's Common Stock which amount consists of 2,030,028 Shares of Common Stock, as well as and the exercise of pre-funded Warrants for 2,000,000 Shares of Common Stock and Class A Warrants for 2,000,000 shares of Common Stock. The amount beneficially owned is reported as of January 2, 2026. Each Reporting Person may be deemed to beneficially own 8.4% of the issuer's outstanding Common Stock, which is calculated based on 67,540,930 shares outstanding of Common Stock as of January 2, 2026, as reported in the Issuer's report on Form 8-K filed with the SEC on January 5, 2026, and the total number of Shares of Common Stock that the Reporting Persons have the right to acquire upon the exercise of Warrants, subject to a 9.9% beneficial ownership limitation, which amount has been added to the shares outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act. 6,030,028. Comment: Shared voting power includes 4,000,000 Warrants beneficially owned by the Reporting Persons. 6,030,028. Comment: Shared dispositive power includes 4,000,000 Warrants beneficially owned by the Reporting Persons. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) StemPoint Capital LP /s/ Sean C. Tan 02/17/2026 StemPoint Capital Management GP LLC /s/ Sean C. Tan 02/17/2026 Michelle Ross /s/ Michelle Ross 02/17/2026